Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Davis

Showing results (511-520 of 529) with videos related to

Pageof 53
Sort By:
Diabetologia|November 6, 2010
Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) StudyT M E Davis, R Ting, J D Best, et al.
Lancet (London, England)|November 9, 2007
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trialA C Keech, P Mitchell, P A Summanen, et al.
The New England Journal of Medicine|December 10, 2008
A trial of combination antimalarial therapies in children from Papua New GuineaHarin A Karunajeewa, Ivo Mueller, Michele Senn, et al.
Diabetes, Obesity & Metabolism|November 21, 2013
Intensification of medication and glycaemic control among patients with type 2 diabetes - the ADVANCE trialS van Dieren, A P Kengne, J Chalmers, et al.
The Lancet. Diabetes & Endocrinology|March 3, 2018
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD studyBoris Waldman, Jean-Claude Ansquer, David R Sullivan, et al.
Plos Medicine|December 31, 2014
Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trialMoses Laman, Brioni R Moore, John M Benjamin, et al.
Plos Medicine|September 14, 2012
Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control studyAnna Rosanas-Urgell, Enmoore Lin, Laurens Manning, et al.
BMC Public Health|August 12, 2021
Prevalence and patterns of multimorbidity in Australian baby boomers: the Busselton healthy ageing studyMichael L Hunter, Matthew W Knuiman, Bill A W Musk, et al.
Diabetes & Metabolism|June 4, 2015
The metabolic syndrome and cancer: Is the metabolic syndrome useful for predicting cancer risk above and beyond its individual components?J Harding, M Sooriyakumaran, K J Anstey, et al.
Contemporary Clinical Trials|November 20, 2019
A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerationsAnne T Reutens, Karin Jandeleit-Dahm, Merlin Thomas, et al.
Pageof 53

Showing results (511-520 of 529) with videos related to

Sort By:
Pageof 53
Diabetologia|November 6, 2010
Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) StudyT M E Davis, R Ting, J D Best, et al.
Lancet (London, England)|November 9, 2007
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trialA C Keech, P Mitchell, P A Summanen, et al.
The New England Journal of Medicine|December 10, 2008
A trial of combination antimalarial therapies in children from Papua New GuineaHarin A Karunajeewa, Ivo Mueller, Michele Senn, et al.
Diabetes, Obesity & Metabolism|November 21, 2013
Intensification of medication and glycaemic control among patients with type 2 diabetes - the ADVANCE trialS van Dieren, A P Kengne, J Chalmers, et al.
The Lancet. Diabetes & Endocrinology|March 3, 2018
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD studyBoris Waldman, Jean-Claude Ansquer, David R Sullivan, et al.
Plos Medicine|December 31, 2014
Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trialMoses Laman, Brioni R Moore, John M Benjamin, et al.
Plos Medicine|September 14, 2012
Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control studyAnna Rosanas-Urgell, Enmoore Lin, Laurens Manning, et al.
BMC Public Health|August 12, 2021
Prevalence and patterns of multimorbidity in Australian baby boomers: the Busselton healthy ageing studyMichael L Hunter, Matthew W Knuiman, Bill A W Musk, et al.
Diabetes & Metabolism|June 4, 2015
The metabolic syndrome and cancer: Is the metabolic syndrome useful for predicting cancer risk above and beyond its individual components?J Harding, M Sooriyakumaran, K J Anstey, et al.
Contemporary Clinical Trials|November 20, 2019
A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerationsAnne T Reutens, Karin Jandeleit-Dahm, Merlin Thomas, et al.
Pageof 53